36 citations
,
November 1995 in “Clinical endocrinology” Low-dose flutamide helps reduce excessive hair growth and is even more effective with birth control, without bad effects on blood fats.
November 2024 in “Skin Appendage Disorders” Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.
January 2018 in “Journal of analytical, bioanalytical and separation techniques” 5 citations
,
May 2022 in “Clinical & Experimental Metastasis” Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.
60 citations
,
June 1997 in “Drugs & Aging” Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.
March 2020 in “DOAJ (DOAJ: Directory of Open Access Journals)” Finasteride may help treat female hair loss, but has risks.
May 2022 in “Current Enzyme Inhibition” Compound 7b is a promising candidate for treating benign prostatic hyperplasia and prostate cancer.
July 2024 in “Journal of Investigative Dermatology” Most women continued using oral minoxidil for hair loss despite mild to moderate side effects.
431 citations
,
October 2008 in “Current Medicinal Chemistry” Coumarin derivatives show promise as anti-estrogenic agents for treating breast cancer, with some in clinical trials.
25 citations
,
December 2017 in “The Journal of Clinical Endocrinology & Metabolism” Birth control pills combined with bicalutamide are more effective at reducing excessive hair growth in women with PCOS than birth control pills alone.
3 citations
,
March 2025 in “Journal of Clinical Medicine” Ritlecitinib effectively treats alopecia areata with manageable side effects.
April 2016 in “The FASEB Journal” Blocking androgen receptors early in life increases estrogen levels and reduces sexual motivation in male rats.
4 citations
,
October 2009 in “International Journal of Endocrinology and Metabolism” Both Diane 35 combinations effectively and safely reduce hirsutism and acne, with potential for better results if treatment extends beyond 12 months.
5 citations
,
January 1991 in “Drugs of The Future” January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
3 citations
,
January 2018 in “Journal of South Asian Federation of Obstetrics and Gynaecology” Letrozole is better for single follicle development and endometrial thickness in PCOS, with no significant difference in pregnancy rates compared to clomiphene.
November 2024 in “Gynecological Endocrinology” The article's findings are uncertain and should be viewed with caution.
26 citations
,
January 2005 in “PubMed” RUM-loaded SLN shows promise for treating acne and hair loss topically.
5 citations
,
February 2024 in “Clinical Pharmacokinetics” A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
11 citations
,
November 2009 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Bolandiol, a synthetic steroid, builds muscle and bone without greatly affecting sex glands, and works differently from other hormones.
October 2015 in “药物不良反应杂志” Stopping the drug usually helps, but tamoxifen or surgery may be needed if symptoms persist.
5 citations
,
August 2021 in “Journal of biological chemistry/The Journal of biological chemistry” Retinoic acid affects male and female muscle energy use and function differently.
August 2007 in “Drug and therapeutics bulletin” Eflornithine's effectiveness for women with facial hirsutism is unclear.
2 citations
,
January 2023 in “Curēus” Low-dose naltrexone may help reduce redness in certain scalp conditions.
4 citations
,
April 2020 in “Dermatology practical & conceptual” Topical finasteride works faster and better than 17α-estradiol for postmenopausal hair loss.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
2-Hydroxy-1,4-naphthoquinone is a strong 5α-reductase inhibitor.
23 citations
,
January 2012 in “International Food Research Journal” Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.
September 2018 in “The Journal of Urology”